Background: There is a need for active agents with a better safety profile than docetaxel, yet good activity, for patients with hormone-refractory prostate cancer (HRPC). We carried out a phase II trial to determine the activity and safety of estramustine plus oral etoposide in HRPC.
introduction
The standard care for hormone-refractory prostate cancer (HRPC) is considered docetaxel every 3 weeks in association with prednisone, which confers a modest survival advantage compared with mitoxantrone plus prednisone [1, 2] . However, the significant toxicity of docetaxel can worsen quality of life, so there is a need to find agents with better safety profile and good activity that can delay the need to administer docetaxel. Estramustine phosphate (EMP) is an estrogenic molecule attached to a nitrogen mustard moiety that inhibits microtubule dynamics and has shown activity alone and in combination with taxanes in HRPC [3] [4] [5] [6] [7] [8] [9] [10] . Importantly, nontaxane-based EMP combinations have shown modest activity in feasibility studies [11] [12] [13] [14] [15] [16] . A phase II study with EMP alone reported serum prostrate-specific antigen (PSA) decrease of 50% or more in 24% of 34 patients with HRPC and better survival in responders than nonresponders [17] . Oral etoposide in association with oral cyclophosphamide or biweekly epidoxorubicin has also shown modest activity in HRPC [18, 19] . Finally, some small studies indicate that EMP plus etoposide is active orally in patients with HRPC [20] [21] [22] .
We carried out a prospective phase II study to further investigate the activity and safety of EMP plus oral etoposide in a large series of patients with HRPC.
patients and methods

patient selection
Patients with histologically documented hormone-refractory metastatic prostate adenocarcinoma were enrolled. Enrollment criteria were two or more consecutive elevations of PSA titer not less than 14 days apart in surgically or chemically castrated patients; age 18 years or older; life expectancy at least 12 weeks; Eastern Cooperative Oncology Group (ECOG) performance status of zero to two; completion of chemotherapy at least 4 weeks previously (6 weeks previously for mitomycin C or a nitrosourea); discontinuation of nonsteroidal antiandrogens at least 4 weeks previously; adequate bone marrow function (hemoglobin 9 g/dl, absolute neutrophil count 1500/ll, platelet count 100 000/ll); adequate liver function (total bilirubin within our Institute's upper limit of normal; serum aspartate and alanine transferases <1.5 times upper normal limit; alkaline phosphatase <2.5 times upper normal limit); adequate renal function (serum creatinine <1.5 times upper normal limit); and no coexisting medical problems of sufficient severity (including thromboembolic disease, stroke, or myocardial infarction) to limit study compliance. The study was approved by our Institute's review board and all patients gave written informed consent before treatment.
treatment
Patients received EMP 280 mg twice daily and oral etoposide 100 mg daily for 21 of 28-day cycles until disease progression or unacceptable toxicity. Patients continued to receive the LHRH analogue leuprorelin (3.75 mg every 28 days) if already on it. For patients with at least one lesion evaluable in two dimensions, response evaluation criteria in solid tumors (RECIST) were used [23] . Complete response was stated as disappearance of all target lesions compared to baseline. Partial response was defined as at least a 30% decrease in the sum of the longest diameter of all target lesions compared to baseline. Otherwise PSA levels were followed. A PSA response was defined as a 50% decrease in PSA compared with pretreatment sustained for at least one course. Progressive disease was defined as a >50% increase in PSA from PSA nadir. Stable disease was defined as a <50% decrease or <50% increase in PSA level over pretreatment PSA levels for at least one course. The National Cancer Institute Common Toxicity Criteria (version 2) were used to assess toxicity [24] .
A 25% reduction in EMP and etoposide dose was planned for persistent G1 nausea, vomiting or other gastrointestinal side-effects, and hematologic toxicity. For grade ‡2 non-hematological toxicity (except alopecia and adequately treated nausea/vomiting) and for grade ‡3 hematological toxicity, treatment was delayed until recovery (£grade 1). More marked reductions including continuation with one drug only were permitted at the treating physician's discretion.
examinations
Complete medical history, physical examination, and routine laboratory studies were carried out at screening, including the following: blood tests (complete blood count, differential white blood cell count, prothrombin and partial thromboplastin times, routine electrolytes and blood chemistry, total protein, and albumin) urinalysis, electrocardiogram, PSA, and radiological studies to assess all disease sites. The radiological evaluations were repeated every 2 months. PSA, physical examination, and routine laboratory tests were repeated monthly or before each new course.
statistical analyses
This was an open-label, nonrandomized phase II study. The primary end point was overall response defined as >50% drop in PSA or as complete or partial response in patients with at least one lesion measurable in two dimensions. Fleming's one-sample multiple testing procedure was used to assess therapeutic efficacy [25] . We considered a PSA response in 30% as clinically significant [1] . Supposing a PSA drop >50% in at least 10% of patients and a PSA drop >50% in 30% as clinically significant, then 78 patients need to be enrolled in the trial to have an 80% (1-b) power of demonstrating efficacy at a = 5%. Median time to progression and median overall survival were represented according Kaplan-Meier [26] . (Table 1) . Median age was 67 years (range 28-84 years). Sixty-one (81%) patients had bone metastases. Eight (10%) patients were assessable only for PSA. Sixty-two (83%) patients received the treatment as first-line therapy after developing hormone-refractory disease. All except three patients who underwent surgical orchiectomy received concomitant leuprorelin. toxicity A total of 337 cycles were administered (median four cycles per patient, range 1-12). All patients were assessable for safety (Table 2) . Four patients received only one cycle: three of whom stopped for toxicity (anemia, nausea, diarrhea), the other for early worsening of clinical condition. Nine patients received their last two cycles without etoposide, and five patients received reduced etoposide after the first cycle (75% reduction in one, 50% reduction in three, 25% reduction in one). Six patients delayed starting subsequent cycles by 1 week due the toxicity (anemia in three, high gamma-glutamyl transferase in one, asthenia in the other). The most frequent grade 1/2 adverse events (>20%) were asthenia, anemia, and nausea. G3/4 toxicity occurred in 17 (22.6%) patients. One patient experienced G4 neutropenia. Five patients developed G3 anemia, three of whom required blood transfusion. Three other patients required low molecular weight heparin for deep vein thrombosis. activity Ten patients with one or more measurable lesions were evaluated by RECIST (Table 3) : two had short-lasting partial remission of lymph node metastases (4 and 5 months); two had shortlasting stable disease (5 and 6 months); six had progressive disease. Six patients were not assessable for PSA: five stopped treatment before completion of two cycles for worsening performance status, and one did not have raised PSA levels. Of the 69 patients assessable for PSA, 14 (20%) had >50% PSA decrease of median duration 5 months (range 4-11); 26 (37.5%) had stable PSA with median time to progression 5 months (range 2-9); 29 had progressive disease. Of the 52 patients with nonmeasurable bone lesions, 15 were not assessable as they stopped treatment for PSA progression or unacceptable toxicity before CT could be carried out, and 17 (32.5%) had stable disease (Table 3) . Overall, median time to progression was 4.4 months (range 1 week-43 months) ( Figure 1 ) and median survival was 23 months (range 3 weeks-64 months at latest follow-up) (Figure 2) . Twenty-seven patients (36%) were alive at latest follow-up and nine (12%) were lost to follow-up. original article
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With the aim of identifying active agents with a better safety profile than docetaxel or mitoxantrone, yet good activity, so as to delay the need to administer docetaxel, we carried out a prospective phase II trial with estramustine plus etoposide, both administered orally. Three small phase II trials (Table 4 ) [20] [21] [22] had indicated that this combination has activity: 80% experienced PSA reduction and 30%-40% of those with measurable lesions had clinical benefit, although doses and study designs differed. Our study, on 75 patients with HRPC, showed that the combination was capable of stabilizing PSA levels (partial response plus stable disease) in 57.5% of assessable patients and stabilizing lesion size in 40% of assessable patients, but only for a limited period (4-5 months). Benefit only occurred in patients with ECOG <2 and hence the combination does not appear appropriate for patients with ECOG 2. Although grade 3/4 toxicity at 22.6% was higher than expected, overall the treatment was manageable and less than encountered with docetaxel. [1] Three patients developed deep vein thrombosis, less than the four (6%) cases reported by Pienta et al. [20] and two (10%) cases reported by Dimopoulos et al. [22] . However, a metaanalysis of 23 studies involving 896 patients treated with estramustine concluded that the risk of thromboembolic events was low (0.07) and not dose related [27] . Two randomized trials investigated estramustine as add-on to docetaxel in HRPC finding no indication that estramustine could increase the benefit of docetaxel [28, 29] . No studies have been designed to determine whether specific subgroups of HRPC patients might benefit from EMP or oral etoposide as individual agents or in combination. A retrospective assessment of 78 patients with HRPC provided no evidence that prior estrogen response predicts response to EMP [30] . However, it seems reasonable that asymptomatic HRPC patients with low Gleason score and low PSA might benefit from the EMP-etoposide combination. To conclude, EMP plus etoposide has shown modest activity and acceptable safety in HRPC patients, suggesting that in asymptomatic patients with nonaggressive disease this combination could be useful to delay the start of more demanding treatments.
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